BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced solid tumours.

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for 13 weeks.

Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. The gold standard ...

A study by Larsen and colleagues has exemplified the role that HCs have in heightening depression risk in this group.

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial.

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

The company will continue with the Phase III trial despite the Phase II failure. Image credit: Shutterstock / R Photography Background. US-based biotech Cerevance is continuing an ongoing pivotal ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.